Kobelt G - Search Results

1

Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets.

Rachev B, Wilking N, Kobelt G, Spandonaro F, Rajer M, Roediger A, Normand R, Zielinski C. Rachev B, et al. Among authors: kobelt g. J Cancer Policy. 2021 Jun;28:100279. doi: 10.1016/j.jcpo.2021.100279. Epub 2021 Feb 26. J Cancer Policy. 2021. PMID: 35559908

2

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.

Wilking N, Bucsics A, Kandolf Sekulovic L, Kobelt G, Laslop A, Makaroff L, Roediger A, Zielinski C. Wilking N, et al. Among authors: kobelt g. ESMO Open. 2019 Nov 13;4(6):e000550. doi: 10.1136/esmoopen-2019-000550. eCollection 2019. ESMO Open. 2019. PMID: 31798977 Free PMC article. Review.

3

Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.

Kobelt G, Jönsson L, Henriksson F, Fredrikson S, Jönsson B. Kobelt G, et al. Int J Technol Assess Health Care. 2000 Summer;16(3):768-80. doi: 10.1017/s0266462300102041. Int J Technol Assess Health Care. 2000. PMID: 11028132

4

Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.

Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P. Kobelt G, et al. Int J Technol Assess Health Care. 2011 Jul;27(3):193-200. doi: 10.1017/S0266462311000195. Epub 2011 Jul 8. Int J Technol Assess Health Care. 2011. PMID: 21736857

5

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.

Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. Kobelt G, et al. Mult Scler. 2008 Jun;14(5):679-90. doi: 10.1177/1352458507086667. Mult Scler. 2008. PMID: 18566030

6

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

Kobelt G, Jönsson L, Fredrikson S. Kobelt G, et al. Eur J Health Econ. 2003;4(1):50-9. doi: 10.1007/s10198-002-0163-0. Eur J Health Econ. 2003. PMID: 15609169

7

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.

Kobelt G, Lindgren P, Singh A, Klareskog L. Kobelt G, et al. Ann Rheum Dis. 2005 Aug;64(8):1174-9. doi: 10.1136/ard.2004.032789. Epub 2005 Feb 11. Ann Rheum Dis. 2005. PMID: 15708879 Free PMC article. Clinical Trial.

8

Costs and quality of life of multiple sclerosis in Sweden.

Berg J, Lindgren P, Fredrikson S, Kobelt G. Berg J, et al. Among authors: kobelt g. Eur J Health Econ. 2006 Sep;7 Suppl 2:S75-85. doi: 10.1007/s10198-006-0379-5. Eur J Health Econ. 2006. PMID: 17310342

9

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun J. Kobelt G, et al. Rheumatology (Oxford). 2004 Sep;43(9):1158-66. doi: 10.1093/rheumatology/keh271. Epub 2004 Jun 29. Rheumatology (Oxford). 2004. PMID: 15226514 Clinical Trial.

10

Costs and quality of life of patients with multiple sclerosis in Europe.

Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Kobelt G, et al. J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):918-26. doi: 10.1136/jnnp.2006.090365. Epub 2006 May 11. J Neurol Neurosurg Psychiatry. 2006. PMID: 16690691 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

120 results

Search Page